DDInter1747 DDInter1700
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency .
Somatrem {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Somatrem {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Somatrem {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvastatin
Somatrem {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Somatrem {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Somatrem may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Somatrem may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Somatrem may lead to a major life threatening interaction when taken with Bexarotene